Headwinds ahead lead us to sharp cut in estimates.

Another deal in obesity strengthens Novo’s position in the field.

Feud at Mediobanca brings uncertainty ahead of the key board on April 24th.

Reassuring press release on US exposure.

New transformation plan is encouraging.

Unconvinced by the Capital Market Day.